following a full submission:
difelikefalin (Kapruvia®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.
SMC restriction: for use in patients with an inadequate response to best supportive care for reducing itch.
Difelikefalin, compared with placebo, improved itch for a greater proportion of patients with moderate-to-severe itch who were undergoing haemodialysis for end-stage renal disease.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- difelikefalin (Kapruvia)
- SMC ID:
- SMC2623
- Indication:
Treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.
- Pharmaceutical company
- Vifor Fresenius Medical Care Renal Pharma UK Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 12 February 2024